Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 2
2016 1
2017 2
2018 4
2019 12
2020 36
2021 53
2022 79
2023 98
2024 133
2025 159
2026 118

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

585 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials.
Bachert C, Han JK, Desrosiers M, Hellings PW, Amin N, Lee SE, Mullol J, Greos LS, Bosso JV, Laidlaw TM, Cervin AU, Maspero JF, Hopkins C, Olze H, Canonica GW, Paggiaro P, Cho SH, Fokkens WJ, Fujieda S, Zhang M, Lu X, Fan C, Draikiwicz S, Kamat SA, Khan A, Pirozzi G, Patel N, Graham NMH, Ruddy M, Staudinger H, Weinreich D, Stahl N, Yancopoulos GD, Mannent LP. Bachert C, et al. Lancet. 2019 Nov 2;394(10209):1638-1650. doi: 10.1016/S0140-6736(19)31881-1. Epub 2019 Sep 19. Lancet. 2019. PMID: 31543428 Clinical Trial.
BACKGROUND: Patients with chronic rhinosinusitis with nasal polyps (CRSwNP) generally have a high symptom burden and poor health-related quality of life, often requiring recurring systemic corticosteroid use and repeated sinus surgery. ...The most comm …
BACKGROUND: Patients with chronic rhinosinusitis with nasal polyps (CRSwNP) generally have a high symptom burden …
Dupilumab versus omalizumab in patients with chronic rhinosinusitis with nasal polyps and coexisting asthma (EVEREST): a multicentre, randomised, double-blind, head-to-head phase 4 trial.
De Corso E, Canonica GW, Heffler E, Springer M, Grzegorzek T, Viana M, Horváth Z, Mullol J, Gevaert P, Michel J, Peters AT, Wagenmann M, Zaghloul S, Zhang M, Corbett M, Nash S, Angello JT, Radwan A, Deniz Y, Martin A, Hellings PW. De Corso E, et al. Lancet Respir Med. 2025 Dec;13(12):1067-1077. doi: 10.1016/S2213-2600(25)00287-5. Epub 2025 Sep 28. Lancet Respir Med. 2025. PMID: 41033334 Clinical Trial.
BACKGROUND: Chronic rhinosinusitis with nasal polyps (CRSwNP) is predominantly driven by type 2 inflammation. ...Patients were randomly assigned (1:1) to subcutaneous dupilumab 300 mg every 2 weeks or omalizumab weight-tiered and IgE-tiered dosi …
BACKGROUND: Chronic rhinosinusitis with nasal polyps (CRSwNP) is predominantly driven by type 2 inflammation. .. …
Efficacy and Safety of Biologics for Chronic Rhinosinusitis With Nasal Polyps: A Meta-Analysis of Real-World Evidence.
Cai S, Xu S, Zhao Y, Zhang L. Cai S, et al. Allergy. 2025 May;80(5):1256-1270. doi: 10.1111/all.16499. Epub 2025 Feb 22. Allergy. 2025. PMID: 39985317 Free PMC article.
Dupilumab, omalizumab, mepolizumab, and benralizumab have demonstrated good efficacy and safety in the treatment of severe uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP) in phase 3 randomised controlled trials (RCTs). ...This sys …
Dupilumab, omalizumab, mepolizumab, and benralizumab have demonstrated good efficacy and safety in the treatment of severe uncontroll …
Dupilumab Versus Mepolizumab for Chronic Rhinosinusitis With Nasal Polyposis: An Indirect Treatment Comparison.
Hopkins C, Han JK, Fokkens W, Wagenmann M, Guyot P, Khan AH, Nash S, Wang Z, Xu Y, Msihid J, Neupane B, Nag A, Bachert C. Hopkins C, et al. J Allergy Clin Immunol Pract. 2024 Dec;12(12):3393-3401.e15. doi: 10.1016/j.jaip.2024.09.015. Epub 2024 Sep 24. J Allergy Clin Immunol Pract. 2024. PMID: 39326524 Free article.
BACKGROUND: Dupilumab and mepolizumab have shown efficacy and safety in treating chronic rhinosinusitis with nasal polyps (CRSwNP). ...METHODS: A systematic literature review identified RCTs of biologics in CRSwNP. A Bucher ITC was performed, in …
BACKGROUND: Dupilumab and mepolizumab have shown efficacy and safety in treating chronic rhinosinusitis with nasal …
Olfactory Outcomes With Dupilumab in Chronic Rhinosinusitis With Nasal Polyps.
Mullol J, Bachert C, Amin N, Desrosiers M, Hellings PW, Han JK, Jankowski R, Vodicka J, Gevaert P, Daizadeh N, Khan AH, Kamat S, Patel N, Graham NMH, Ruddy M, Staudinger H, Mannent LP. Mullol J, et al. J Allergy Clin Immunol Pract. 2022 Apr;10(4):1086-1095.e5. doi: 10.1016/j.jaip.2021.09.037. Epub 2021 Oct 7. J Allergy Clin Immunol Pract. 2022. PMID: 34628065 Free article. Clinical Trial.
BACKGROUND: Loss of smell (LoS) is one of the most troublesome and difficult-to-treat symptoms of severe chronic rhinosinusitis with nasal polyps (CRSwNP). OBJECTIVE: To assess the impact of dupilumab on sense of smell in severe CRSwNP. ...Du …
BACKGROUND: Loss of smell (LoS) is one of the most troublesome and difficult-to-treat symptoms of severe chronic rhinosinusitis …
Chronic rhinosinusitis with nasal polyps (CRSwNP) treated with omalizumab, dupilumab, or mepolizumab: A systematic review of the current knowledge towards an attempt to compare agents' efficacy.
Papacharalampous GX, Constantinidis J, Fotiadis G, Zhang N, Bachert C, Katotomichelakis M. Papacharalampous GX, et al. Int Forum Allergy Rhinol. 2024 Jan;14(1):96-109. doi: 10.1002/alr.23234. Epub 2023 Jul 18. Int Forum Allergy Rhinol. 2024. PMID: 37394893
BACKGROUND: The heterogeneity of existing studies, along with the fact that there are no published head-to-head trials, are the main reasons for the lack of guidelines regarding the selection of the proper biologic in treatment of chronic rhinosinusitis (CRS) with …
BACKGROUND: The heterogeneity of existing studies, along with the fact that there are no published head-to-head trials, are the main reasons …
Dupilumab in the treatment of severe uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP): A multicentric observational Phase IV real-life study (DUPIREAL).
De Corso E, Pasquini E, Trimarchi M, La Mantia I, Pagella F, Ottaviano G, Garzaro M, Pipolo C, Torretta S, Seccia V, Cantone E, Ciofalo A, Lucidi D, Fadda GL, Pafundi PC, Settimi S, Montuori C, Anastasi F, Pagliuca G, Ghidini A, Cavaliere C, Maffei M, Bussu F, Gallo S, Canevari FRM, Paludetti G, Galli J; Dupireal Italian Study Group. De Corso E, et al. Allergy. 2023 Oct;78(10):2669-2683. doi: 10.1111/all.15772. Epub 2023 May 26. Allergy. 2023. PMID: 37203259 Free article.
BACKGROUND: Chronic rhinosinusitis with nasal polyps (CRSwNP) is associated with significant morbidity and reduced health-related quality of life. ...We collected data at baseline and after 1, 3, 6, 9, and 12 months of follow-up. We focused on nasal …
BACKGROUND: Chronic rhinosinusitis with nasal polyps (CRSwNP) is associated with significant morbidity and reduc …
Effect of Dupilumab on Blood Eosinophil Counts in Patients With Asthma, Chronic Rhinosinusitis With Nasal Polyps, Atopic Dermatitis, or Eosinophilic Esophagitis.
Wechsler ME, Klion AD, Paggiaro P, Nair P, Staumont-Salle D, Radwan A, Johnson RR, Kapoor U, Khokhar FA, Daizadeh N, Chen Z, Laws E, Ortiz B, Jacob-Nara JA, Mannent LP, Rowe PJ, Deniz Y. Wechsler ME, et al. J Allergy Clin Immunol Pract. 2022 Oct;10(10):2695-2709. doi: 10.1016/j.jaip.2022.05.019. Epub 2022 May 28. J Allergy Clin Immunol Pract. 2022. PMID: 35636689 Free article.
BACKGROUND: Transient increases in blood eosinophil counts have been observed in dupilumab clinical trials. OBJECTIVE: To assess eosinophil counts and eosinophilia-related treatment-emergent adverse events (TEAEs) across 11 dupilumab clinical trials, comparing adult …
BACKGROUND: Transient increases in blood eosinophil counts have been observed in dupilumab clinical trials. OBJECTIVE: To assess eosi …
Clinical efficacy and mechanisms of biologics for chronic rhinosinusitis with nasal polyps.
Kratchmarov R, Dharia T, Buchheit K. Kratchmarov R, et al. J Allergy Clin Immunol. 2025 May;155(5):1401-1410. doi: 10.1016/j.jaci.2025.03.011. Epub 2025 Mar 23. J Allergy Clin Immunol. 2025. PMID: 40132672 Free PMC article. Review.
The management of chronic rhinosinusitis with nasal polyps (CRSwNP) can be challenging, particularly when standard treatments including intranasal corticosteroids and endoscopic sinus surgery do not result in adequate symptom control. ...There are curr …
The management of chronic rhinosinusitis with nasal polyps (CRSwNP) can be challenging, particularly when standa …
Biologics for chronic rhinosinusitis with nasal polyps.
Bachert C, Zhang N, Cavaliere C, Weiping W, Gevaert E, Krysko O. Bachert C, et al. J Allergy Clin Immunol. 2020 Mar;145(3):725-739. doi: 10.1016/j.jaci.2020.01.020. J Allergy Clin Immunol. 2020. PMID: 32145872 Review.
Finally, the biologic versus placebo treatment reduced the need for systemic glucocorticosteroids and sinus surgery significantly and clinically meaningfully. Dupilumab today is registered for the treatment of chronic rhinosinusitis with nasal polyp …
Finally, the biologic versus placebo treatment reduced the need for systemic glucocorticosteroids and sinus surgery significantly and clinic …
585 results